S&P 500   3,957.56 (+0.22%)
DOW   32,144.21 (+0.12%)
QQQ   309.98 (+0.07%)
AAPL   159.77 (+0.53%)
MSFT   278.98 (+0.48%)
META   205.50 (+0.60%)
GOOGL   105.05 (-0.52%)
AMZN   97.86 (-0.86%)
TSLA   190.25 (-1.02%)
NVDA   266.16 (-2.11%)
NIO   9.02 (-2.70%)
BABA   86.61 (+0.10%)
AMD   97.87 (-2.40%)
T   18.58 (+0.65%)
F   11.46 (+0.35%)
MU   60.81 (-0.86%)
CGC   1.92 (+0.52%)
GE   91.00 (-0.64%)
DIS   93.90 (-2.01%)
AMC   4.50 (+0.67%)
PFE   40.37 (+0.47%)
PYPL   73.38 (+1.13%)
NFLX   328.30 (+2.48%)
S&P 500   3,957.56 (+0.22%)
DOW   32,144.21 (+0.12%)
QQQ   309.98 (+0.07%)
AAPL   159.77 (+0.53%)
MSFT   278.98 (+0.48%)
META   205.50 (+0.60%)
GOOGL   105.05 (-0.52%)
AMZN   97.86 (-0.86%)
TSLA   190.25 (-1.02%)
NVDA   266.16 (-2.11%)
NIO   9.02 (-2.70%)
BABA   86.61 (+0.10%)
AMD   97.87 (-2.40%)
T   18.58 (+0.65%)
F   11.46 (+0.35%)
MU   60.81 (-0.86%)
CGC   1.92 (+0.52%)
GE   91.00 (-0.64%)
DIS   93.90 (-2.01%)
AMC   4.50 (+0.67%)
PFE   40.37 (+0.47%)
PYPL   73.38 (+1.13%)
NFLX   328.30 (+2.48%)
S&P 500   3,957.56 (+0.22%)
DOW   32,144.21 (+0.12%)
QQQ   309.98 (+0.07%)
AAPL   159.77 (+0.53%)
MSFT   278.98 (+0.48%)
META   205.50 (+0.60%)
GOOGL   105.05 (-0.52%)
AMZN   97.86 (-0.86%)
TSLA   190.25 (-1.02%)
NVDA   266.16 (-2.11%)
NIO   9.02 (-2.70%)
BABA   86.61 (+0.10%)
AMD   97.87 (-2.40%)
T   18.58 (+0.65%)
F   11.46 (+0.35%)
MU   60.81 (-0.86%)
CGC   1.92 (+0.52%)
GE   91.00 (-0.64%)
DIS   93.90 (-2.01%)
AMC   4.50 (+0.67%)
PFE   40.37 (+0.47%)
PYPL   73.38 (+1.13%)
NFLX   328.30 (+2.48%)
S&P 500   3,957.56 (+0.22%)
DOW   32,144.21 (+0.12%)
QQQ   309.98 (+0.07%)
AAPL   159.77 (+0.53%)
MSFT   278.98 (+0.48%)
META   205.50 (+0.60%)
GOOGL   105.05 (-0.52%)
AMZN   97.86 (-0.86%)
TSLA   190.25 (-1.02%)
NVDA   266.16 (-2.11%)
NIO   9.02 (-2.70%)
BABA   86.61 (+0.10%)
AMD   97.87 (-2.40%)
T   18.58 (+0.65%)
F   11.46 (+0.35%)
MU   60.81 (-0.86%)
CGC   1.92 (+0.52%)
GE   91.00 (-0.64%)
DIS   93.90 (-2.01%)
AMC   4.50 (+0.67%)
PFE   40.37 (+0.47%)
PYPL   73.38 (+1.13%)
NFLX   328.30 (+2.48%)
NASDAQ:ATXS

Astria Therapeutics - ATXS Stock Forecast, Price & News

$12.28
+0.80 (+6.97%)
(As of 03/24/2023 02:52 PM ET)
Add
Compare
Today's Range
$11.21
▼
$12.33
50-Day Range
$11.20
▼
$15.52
52-Week Range
$2.36
▼
$16.28
Volume
187,173 shs
Average Volume
233,814 shs
Market Capitalization
$206.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.00

Astria Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
66.5% Upside
$20.00 Price Target
Short Interest
Healthy
1.44% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.18mentions of Astria Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.56) to ($2.67) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.12 out of 5 stars

Medical Sector

305th out of 989 stocks

Pharmaceutical Preparations Industry

129th out of 480 stocks

See Top Rated MarketRank™ Stocks Here

ATXS stock logo

About Astria Therapeutics (NASDAQ:ATXS) Stock

Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is STAR-0215, which is intended to treat Hereditary Angioedema, a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen, and airway. The company was founded by Michael R. Jirousek, Jill C. Milne and Steven E. Shoelson on June 26, 2008 and is headquartered in Boston, MA.

Receive ATXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Astria Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ATXS Stock News Headlines

March 23, 2023 | markets.businessinsider.com
Astria Therapeutics (ATXS) Receives a Buy from LifeSci Capital
March 22, 2023 | businesswire.com
Astria Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update
March 24, 2023 | Legacy Research (Affiliate) (Ad)
"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast
March 20, 2023 | americanbankingnews.com
Astria Therapeutics (ATXS) to Release Quarterly Earnings on Wednesday
March 8, 2023 | finance.yahoo.com
Astria Therapeutics to Report Fourth Quarter/Full Year 2022 Financial Results and Recent Corporate Developments on Wednesday, March 22nd
March 6, 2023 | finance.yahoo.com
Astria Therapeutics to Present at Upcoming Oppenheimer 33rd Annual Healthcare Conference
March 4, 2023 | morningstar.com
Thinking about buying stock in Troika Media, Nio, Lucira Health, Transocean, or Astria Therapeutics?
February 24, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Opko Health (OPK) and Astria Therapeutics (ATXS)
March 24, 2023 | Behind the Markets (Ad)
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
February 24, 2023 | finance.yahoo.com
Astria Therapeutics Presents Additional Data Supporting STAR-0215 Profile as a Long-Acting Preventative Therapy for Hereditary Angioedema at the 2023 American Academy of Allergy, Asthma, and Immunology Annual Meeting
February 21, 2023 | finance.yahoo.com
Astria Therapeutics to Present New STAR-0215 Data at the 2023 American Academy of Allergy, Asthma, and Immunology Annual Meeting
February 15, 2023 | finance.yahoo.com
Astria Therapeutics, Inc. (NASDAQ:ATXS) is a favorite amongst institutional investors who own 55%
February 8, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Astria Therapeutics (ATXS) and SeqLL (SQL)
February 8, 2023 | finance.yahoo.com
Astria Therapeutics Initiates ALPHA-STAR Phase 1b/2 Clinical Trial of STAR-0215 in People with HAE
January 27, 2023 | finance.yahoo.com
Here's What Could Help Astria Therapeutics, Inc. (ATXS) Maintain Its Recent Price Strength
December 27, 2022 | finance.yahoo.com
What Makes Astria Therapeutics, Inc. (ATXS) a Good Fit for 'Trend Investing'
December 27, 2022 | finance.yahoo.com
Does Astria Therapeutics, Inc. (ATXS) Have the Potential to Rally 70% as Wall Street Analysts Expect?
December 20, 2022 | seekingalpha.com
ATXS Astria Therapeutics, Inc.
December 19, 2022 | finance.yahoo.com
Astria Therapeutics Announces Closing of Underwritten Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
December 15, 2022 | finance.yahoo.com
Astria Therapeutics' Potential Hereditary Angioedema Candidate Shows Encouraging Action In Healthy Participants
December 15, 2022 | msn.com
Astria's hereditary angioedema drug shows promise in healthy people in phase 1 trial
December 15, 2022 | markets.businessinsider.com
Astria Reports Positive Preliminary Results From Phase 1a Trial Of STAR-0215
December 15, 2022 | markets.businessinsider.com
Astria Therapeutics Prices Offering Of 9.08 Mln Shares At $11.01/Shr
December 15, 2022 | finance.yahoo.com
Astria Therapeutics Announces Positive Preliminary Results from the Phase 1a Clinical Trial of STAR-0215 in Healthy Subjects
December 15, 2022 | finance.yahoo.com
Astria Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock
November 11, 2022 | markets.businessinsider.com
Ladenburg Thalmann & Co. Reaffirms Their Buy Rating on Astria Therapeutics (ATXS)
November 11, 2022 | markets.businessinsider.com
H.C. Wainwright Remains a Buy on Astria Therapeutics (ATXS)
See More Headlines
Receive ATXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Astria Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ATXS Company Calendar

Last Earnings
11/10/2021
Today
3/24/2023
Next Earnings (Estimated)
5/11/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ATXS
CUSIP
N/A
CIK
1454789
Web
www.catabasis.com
Phone
(617) 349-1971
Fax
617-273-2637
Employees
29
Year Founded
2008

Price Target and Rating

Average Stock Price Forecast
$20.00
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$20.00
Forecasted Upside/Downside
+74.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($3.64)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-194,910,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-327.59%
Return on Assets
-41.15%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
18.40
Quick Ratio
18.40

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.99 per share
Price / Book
5.77

Miscellaneous

Outstanding Shares
16,830,000
Free Float
16,153,000
Market Cap
$193.21 million
Optionable
Not Optionable
Beta
0.90

Social Links


Key Executives

  • Jill C. Milne
    President, Chief Executive Officer & Director
  • Noah Clauser
    Chief Financial Officer
  • Maria C. Mancini
    Vice President-Clinical Operations
  • Andrew Nichols
    Chief Scientific Officer
  • Christopher J Morabito
    Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













ATXS Stock - Frequently Asked Questions

Should I buy or sell Astria Therapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Astria Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATXS shares.
View ATXS analyst ratings or view top-rated stocks.

What is Astria Therapeutics' stock price forecast for 2023?

2 analysts have issued twelve-month target prices for Astria Therapeutics' stock. Their ATXS share price forecasts range from $20.00 to $20.00. On average, they anticipate the company's share price to reach $20.00 in the next twelve months. This suggests a possible upside of 74.2% from the stock's current price.
View analysts price targets for ATXS or view top-rated stocks among Wall Street analysts.

How have ATXS shares performed in 2023?

Astria Therapeutics' stock was trading at $14.89 at the beginning of the year. Since then, ATXS stock has decreased by 22.9% and is now trading at $11.48.
View the best growth stocks for 2023 here.

When is Astria Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023.
View our ATXS earnings forecast.

How were Astria Therapeutics' earnings last quarter?

Astria Therapeutics, Inc. (NASDAQ:ATXS) released its quarterly earnings results on Wednesday, November, 10th. The biotechnology company reported ($0.61) earnings per share for the quarter, topping analysts' consensus estimates of ($0.92) by $0.31. During the same quarter in the previous year, the business posted ($3.36) earnings per share.

What ETFs hold Astria Therapeutics' stock?

ETFs with the largest weight of Astria Therapeutics (NASDAQ:ATXS) stock in their portfolio include AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC).

When did Astria Therapeutics' stock split?

Astria Therapeutics shares reverse split on the morning of Friday, August 20th 2021. The 1-6 reverse split was announced on Friday, August 20th 2021. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 20th 2021. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

What is Astria Therapeutics' stock symbol?

Astria Therapeutics trades on the NASDAQ under the ticker symbol "ATXS."

Who are Astria Therapeutics' major shareholders?

Astria Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Fairmount Funds Management LLC (11.30%), Vivo Capital LLC (9.99%), Driehaus Capital Management LLC (7.95%), Sphera Funds Management LTD. (2.79%), Opaleye Management Inc. (1.55%) and Point72 Asset Management L.P. (1.34%). Insiders that own company stock include Andrew Komjathy and Perceptive Advisors Llc.
View institutional ownership trends.

How do I buy shares of Astria Therapeutics?

Shares of ATXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Astria Therapeutics' stock price today?

One share of ATXS stock can currently be purchased for approximately $11.48.

How much money does Astria Therapeutics make?

Astria Therapeutics (NASDAQ:ATXS) has a market capitalization of $193.21 million. The biotechnology company earns $-194,910,000.00 in net income (profit) each year or ($3.64) on an earnings per share basis.

How can I contact Astria Therapeutics?

Astria Therapeutics' mailing address is 100 High StreetFloor 28, Boston MA, 02110. The official website for the company is www.catabasis.com. The biotechnology company can be reached via phone at (617) 349-1971, via email at info@astriatx.com, or via fax at 617-273-2637.

This page (NASDAQ:ATXS) was last updated on 3/24/2023 by MarketBeat.com Staff